Cell‐free DNA levels are increased in acute graft‐versus‐host disease

Background Cell‐free DNA (cfDNA) and nucleosomes, consisting of cfDNA and histones, are markers of cell activation and damage. In systemic inflammation these markers predict severity and fatality. However, the role of cfDNA in acute Graft‐versus‐Host Disease (aGvHD), a major complication of allogene...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of haematology 2022-09, Vol.109 (3), p.271-281
Hauptverfasser: Kroeze, Anna, Cornelissen, Anne S., Pascutti, M. Fernanda, Verheij, Myrddin, Bulder, Ingrid, Klarenbeek, Sjoerd, Ait Soussan, Aicha, Hazenberg, Mette D., Nur, Erfan, Schoot, C. Ellen, Voermans, Carlijn, Zeerleder, Sacha S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Cell‐free DNA (cfDNA) and nucleosomes, consisting of cfDNA and histones, are markers of cell activation and damage. In systemic inflammation these markers predict severity and fatality. However, the role of cfDNA in acute Graft‐versus‐Host Disease (aGvHD), a major complication of allogeneic hematopoietic stem cell transplantation (HSCT), is unknown. Objective The aim of this study is to investigate the role of cfDNA as a marker of aGvHD. Methods We followed nucleosome levels in 37 allogeneic HSCT patients and an established xenotransplantation mouse model. We determined the origin of cfDNA with a species‐specific polymerase chain reaction. Results In the plasma of aGvHD patients, nucleosome levels significantly increased around the time of aGvHD diagnosis compared to pretransplant, concurrently with a significant increase of known aGvHD markers ST2 and REG3α. In mice, we confirmed that nucleosomes were elevated during clinically detectable aGvHD. We found cfDNA to be mainly of human origin and to a lesser extent of mouse origin, indicating that cfDNA is released by (proliferating) human xeno‐reactive PBMC and damaged mouse cells. Conclusion We show increased cfDNA both in an aGvHD mouse model and in aGvHD patients. We also demonstrate that donor hematopoietic cells and to a lesser degree (damaged) host cells are the cellular source of cfDNA in aGvHD. We propose that nucleosomes and cfDNA might be an additive marker for aGvHD.
ISSN:0902-4441
1600-0609
DOI:10.1111/ejh.13806